{"disease":{"id":"pancreatic-tumor","name":"pancreatic tumor"},"drugs":{"marketed":[{"drug_id":"everolimus","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"streptozocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanosar","generic_name":"STREPTOZOCIN","company_name":"Teva","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sunitinib-malate","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"afinitor","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sutent","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumors (pNET)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"streptozotocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Streptozotocin","company_name":"Hoffmann-La Roche","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT04949282","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Sociedad Española de Medicina Nuclear e Imagen Molecular","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04282083","title":"Protocol ITANET - Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Italian Association Neuroendocrine Tumors","has_results":false},{"nct_id":"NCT07414004","title":"Comparison of Prognosis Between Open Pancreatic Surgery With Vein Resection and Reconstruction Versus Minimally Invasive Pancreatic Surgery With Vein Resection and Reconstruction for Pancreatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2451,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06041009","title":"Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations","phase":"","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT07439757","title":"AI-Powered Precision Decision-Making for Pancreatic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT05847855","title":"Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03084770","title":"Asymptomatic Small Pancreatic Endocrine Neoplasms.","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06641947","title":"Differentiation Benign and Malignant Pancreatic Lesions","phase":"","overall_status":"COMPLETED","enrollment_count":864,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05907824","title":"Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04074135","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07034495","title":"Laparotomy, Laparoscopy, da Vinci System","phase":"","overall_status":"COMPLETED","enrollment_count":486,"lead_sponsor_name":"National Chung Hsing University","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03222258","title":"Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02630654","title":"Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs","phase":"","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04986085","title":"Nutrition in Gastroenteropancreatic Neuroendocrine Tumor","phase":"","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT02009449","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT05245500","title":"Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":322,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07529626","title":"Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":320,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT05794048","title":"METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05608538","title":"Evaluation of Nutritional Scores as Predictive Factors of Postoperative Outcome After Pancreatic Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT06155318","title":"68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT07329920","title":"Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT03375320","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":298,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04925284","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04400357","title":"Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04136522","title":"Usefulness of the Artery First Approach in Pancreatic Cancer Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":268,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05636618","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06403735","title":"A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07165886","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":243,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06167421","title":"Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06784752","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT03435588","title":"Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) With Rapid On-site Evaluation (ROSE) of Cytopathology vs. EUS-guided Fine Needle Biopsy (FNB) Alone in the Diagnosis of Pancreatic Solid Lesions","phase":"NA","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}